{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:54:24Z","timestamp":1782996864872,"version":"3.54.5"},"reference-count":227,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06805-8","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:04:57Z","timestamp":1771506297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biomarkers and advances in AML-MRC: from bench to bedside"],"prefix":"10.1007","volume":"105","author":[{"given":"Fanlin","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Al-Khafaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khursheed","family":"Muzammil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Sarbazjoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Navid","family":"Khaksari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Bayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"3","key":"6805_CR1","first-page":"188","volume":"38","author":"L Wang","year":"2021","unstructured":"Wang L et al (2021) Clinical characteristics and optimal therapy of acute myeloid leukemia with Myelodysplasia-Related changes: A retrospective analysis of a cohort of Chinese patients. Turk J Haematol 38(3):188\u2013194","journal-title":"Turk J Haematol"},{"issue":"9825","key":"6805_CR2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S et al (2012) Effect of Gemtuzumab Ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508\u20131516","journal-title":"Lancet"},{"issue":"5","key":"6805_CR3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute myeloid leukemia: 2025 update on Diagnosis, Risk-Stratification, and management. Am J Hematol 100(5):860\u2013891","journal-title":"Am J Hematol"},{"issue":"11","key":"6805_CR4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"7","key":"6805_CR5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"6","key":"6805_CR6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ajcp\/aqaa107","volume":"154","author":"DA Arber","year":"2020","unstructured":"Arber DA, Erba HP (2020) Diagnosis and treatment of patients with acute myeloid leukemia with Myelodysplasia-Related changes (AML-MRC). Am J Clin Pathol 154(6):731\u2013741","journal-title":"Am J Clin Pathol"},{"issue":"Supplement1","key":"6805_CR7","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2019-128234","volume":"134","author":"C Baer","year":"2019","unstructured":"Baer C et al (2019) Molecular classification of AML-MRC reveals a distinct profile and identifies MRC-like patients with poor overall survival. Blood 134(Supplement1):2735\u20132735","journal-title":"Blood"},{"issue":"6","key":"6805_CR8","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.5001\/omj.2021.108","volume":"36","author":"HM Rasheed","year":"2021","unstructured":"Rasheed HM et al (2021) Identifying leukemia-associated immunophenotypes in acute myeloid leukemia patients using multiparameter flow cytometry. Oman Med J 36(6):e323","journal-title":"Oman Med J"},{"issue":"2","key":"6805_CR9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani D et al (2022) Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov 12(2):388\u2013401","journal-title":"Cancer Discov"},{"key":"6805_CR10","doi-asserted-by":"crossref","unstructured":"Kishtagari A, Levine RL (2021) The role of somatic mutations in acute myeloid leukemia pathogenesis. Cold Spring Harb Perspect Med, 11(4)","DOI":"10.1101\/cshperspect.a034975"},{"issue":"19","key":"6805_CR11","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","volume":"118","author":"C Ustun","year":"2011","unstructured":"Ustun C et al (2011) Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 118(19):5084\u20135095","journal-title":"Blood"},{"issue":"1","key":"6805_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady M et al (2025) Adoptive NK cell therapy in AML: progress and challenges. Clin Exp Med 25(1):41","journal-title":"Clin Exp Med"},{"issue":"12","key":"6805_CR13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/jclinpath-2018-205348","volume":"71","author":"KC Dannheim","year":"2018","unstructured":"Dannheim KC et al (2018) Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and <\u2009em\u2009>\u2009TP53\u2009mutations. J Clin Pathol 71(12):1051\u20131059","journal-title":"J Clin Pathol"},{"issue":"Supplement 1","key":"6805_CR14","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2024-201701","volume":"144","author":"R Gunaratne","year":"2024","unstructured":"Gunaratne R et al (2024) Circulating tumor DNA (ctDNA) enables superior and universal measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) highly predictive of relapse free and overall survival. Blood 144(Supplement 1):2955\u20132955","journal-title":"Blood"},{"key":"6805_CR15","doi-asserted-by":"crossref","unstructured":"Jiang A et al (2023) Editorial: Multi-omics approaches for decoding heterogeneity in cancer immunotherapy. Front Pharmacol, Volume 14\u20132023","DOI":"10.3389\/fphar.2023.1324212"},{"issue":"36","key":"6805_CR16","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2217\/fon-2022-0334","volume":"18","author":"V Kota","year":"2022","unstructured":"Kota V et al (2022) Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. Future Oncol 18(36):4017\u20134029","journal-title":"Future Oncol"},{"issue":"1","key":"6805_CR17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M et al (2025) The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Experimental Med 25(1):230","journal-title":"Clin Experimental Med"},{"issue":"4","key":"6805_CR18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2643-3230.BCD-21-0128","volume":"3","author":"T Guess","year":"2022","unstructured":"Guess T et al (2022) Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia. Blood Cancer Discov 3(4):316\u2013329","journal-title":"Blood Cancer Discov"},{"key":"6805_CR19","doi-asserted-by":"crossref","unstructured":"Koenig KL et al (2020) AML with Myelodysplasia-Related changes: Development, Challenges, and treatment advances. Genes (Basel), 11(8)","DOI":"10.3390\/genes11080845"},{"issue":"7714","key":"6805_CR20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S et al (2018) Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559(7714):400\u2013404","journal-title":"Nature"},{"key":"6805_CR21","doi-asserted-by":"crossref","unstructured":"Weeks LD et al (2023) Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid, 2(5)","DOI":"10.1056\/EVIDoa2200310"},{"key":"6805_CR22","doi-asserted-by":"crossref","unstructured":"Rasmussen B et al (2022) Randomized phase II study of azacitidine\u2009\u00b1\u2009lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q). Leukemia, 36(5): pp. 1436\u20131439","DOI":"10.1038\/s41375-022-01537-w"},{"issue":"2","key":"6805_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-021-00416-4","volume":"11","author":"BA Pitel","year":"2021","unstructured":"Pitel BA et al (2021) Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer J 11(2):18","journal-title":"Blood Cancer J"},{"issue":"1","key":"6805_CR24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2063","volume":"16","author":"JL Barlow","year":"2010","unstructured":"Barlow JL et al (2010) A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q\u2013 syndrome. Nat Med 16(1):59\u201366","journal-title":"Nat Med"},{"issue":"1","key":"6805_CR25","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas HA et al (2021) Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 Blockade therapy. Nat Commun 12(1):6071","journal-title":"Nat Commun"},{"issue":"1","key":"6805_CR26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ng.2846","volume":"46","author":"CC Wong","year":"2014","unstructured":"Wong CC et al (2014) Inactivating CUX1 mutations promote tumorigenesis. Nat Genet 46(1):33\u201338","journal-title":"Nat Genet"},{"issue":"3","key":"6805_CR27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ccr.2013.08.011","volume":"24","author":"A Nagamachi","year":"2013","unstructured":"Nagamachi A et al (2013) Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. Cancer Cell 24(3):305\u2013317","journal-title":"Cancer Cell"},{"key":"6805_CR28","doi-asserted-by":"crossref","unstructured":"Al-Bulushi F et al (2022) Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis. Front Oncol, Volume 12\u20132022","DOI":"10.3389\/fonc.2022.967657"},{"issue":"7","key":"6805_CR29","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41375-022-01631-z","volume":"36","author":"I Fuhrmann","year":"2022","unstructured":"Fuhrmann I et al (2022) AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics. Leukemia 36(7):1939\u20131942","journal-title":"Leukemia"},{"issue":"1","key":"6805_CR30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL et al (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Therapy 5(1):288","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"6805_CR31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-019-03606-0","volume":"98","author":"E Cheung","year":"2019","unstructured":"Cheung E et al (2019) The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol 98(3):541\u2013559","journal-title":"Ann Hematol"},{"issue":"1","key":"6805_CR32","doi-asserted-by":"crossref","first-page":"40707","DOI":"10.1038\/srep40707","volume":"7","author":"MR Lopes","year":"2017","unstructured":"Lopes MR et al (2017) De Novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Sci Rep 7(1):40707","journal-title":"Sci Rep"},{"issue":"3","key":"6805_CR33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.leu.2405076","volume":"22","author":"TC Huang","year":"2008","unstructured":"Huang TC et al (2008) Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-\/hypercellular MDS by international prognostic scoring System, cytogenetic and genetic studies. Leukemia 22(3):544\u2013550","journal-title":"Leukemia"},{"issue":"5","key":"6805_CR34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","volume":"27","author":"MG Della Porta","year":"2009","unstructured":"Della Porta MG et al (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27(5):754\u2013762","journal-title":"J Clin Oncol"},{"issue":"2","key":"6805_CR35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12308-011-0088-6","volume":"4","author":"A Porwit","year":"2011","unstructured":"Porwit A, Saft L (2011) The AML\u2013MDS interface\u2014leukemic transformation in myelodysplastic syndromes. J Hematopathology 4(2):69\u201379","journal-title":"J Hematopathology"},{"key":"6805_CR36","doi-asserted-by":"crossref","first-page":"40707","DOI":"10.1038\/srep40707","volume":"7","author":"MR Lopes","year":"2017","unstructured":"Lopes MR et al (2017) De Novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. Sci Rep 7:40707","journal-title":"Sci Rep"},{"issue":"11","key":"6805_CR37","first-page":"1200","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood J Am Soc Hematol 140(11):1200\u20131228","journal-title":"Blood J Am Soc Hematol"},{"issue":"19","key":"6805_CR38","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.3390\/ijms221910782","volume":"22","author":"B George","year":"2021","unstructured":"George B et al (2021) TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J Mol Sci 22(19):10782","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6805_CR39","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG et al (2022) TP53-Mutated myelodysplastic syndrome and acute myeloid leukemia: Biology, current Therapy, and future directions. Cancer Discov 12(11):2516\u20132529","journal-title":"Cancer Discov"},{"issue":"15","key":"6805_CR40","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T et al (2022) Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 139(15):2347\u20132354","journal-title":"Blood"},{"issue":"17","key":"6805_CR41","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1182\/bloodadvances.2023009675","volume":"7","author":"JGW McCarter","year":"2023","unstructured":"McCarter JGW et al (2023) Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv 7(17):5000\u20135013","journal-title":"Blood Adv"},{"issue":"3","key":"6805_CR42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","volume":"104","author":"TP Katharina","year":"2019","unstructured":"Katharina TP et al (2019) Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica 104(3):516\u2013523","journal-title":"Haematologica"},{"issue":"1","key":"6805_CR43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith SM et al (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the university of Chicago series. Blood 102(1):43\u201352","journal-title":"Blood"},{"issue":"7540","key":"6805_CR44","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518(7540):552\u2013555","journal-title":"Nature"},{"issue":"7","key":"6805_CR45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P et al (2018) Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 24(7):1015\u20131023","journal-title":"Nat Med"},{"issue":"21","key":"6805_CR46","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/bloodadvances.2021004668","volume":"5","author":"A Stengel","year":"2021","unstructured":"Stengel A et al (2021) Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv 5(21):4426\u20134434","journal-title":"Blood Adv"},{"issue":"9","key":"6805_CR47","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK et al (2022) TP53 mutation defines a unique subgroup within complex karyotype de Novo and therapy-related MDS\/AML. Blood Adv 6(9):2847\u20132853","journal-title":"Blood Adv"},{"issue":"6","key":"6805_CR48","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1002\/cam4.5421","volume":"12","author":"D Zhao","year":"2023","unstructured":"Zhao D et al (2023) Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency. Cancer Med 12(6):6511\u20136522","journal-title":"Cancer Med"},{"key":"6805_CR49","doi-asserted-by":"crossref","unstructured":"Shin DY (2023) TP53 mutation in acute myeloid leukemia: an old foe revisited. Cancers (Basel), 15(19)","DOI":"10.3390\/cancers15194816"},{"issue":"2","key":"6805_CR50","first-page":"145","volume":"43","author":"A Yokota","year":"2020","unstructured":"Yokota A et al (2020) The Clinical, Molecular, and mechanistic basis of RUNX1 mutations identified in hematological malignancies. Mol Cells 43(2):145\u2013152","journal-title":"Mol Cells"},{"issue":"5","key":"6805_CR51","first-page":"472","volume":"11","author":"H Goel","year":"2021","unstructured":"Goel H et al (2021) Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. Am J Blood Res 11(5):472","journal-title":"Am J Blood Res"},{"issue":"1","key":"6805_CR52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang HM et al (2015) Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21(1):37\u201346","journal-title":"Nat Med"},{"issue":"4","key":"6805_CR53","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.31557\/APJCP.2022.23.4.1107","volume":"23","author":"N Sutandyo","year":"2022","unstructured":"Sutandyo N et al (2022) Association of somatic gene mutations with risk of transformation into acute myeloid leukemia in patients with myelodysplastic syndrome: A systematic review and meta-analysis. Asian Pac J Cancer Prevention: APJCP 23(4):1107","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"6","key":"6805_CR54","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/10428194.2020.1723016","volume":"61","author":"L Nguyen","year":"2020","unstructured":"Nguyen L et al (2020) Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1. Leuk Lymphoma 61(6):1395\u20131405","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6805_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3343\/alm.2024.0477","volume":"45","author":"TS Kendrick","year":"2025","unstructured":"Kendrick TS et al (2025) Abnormalities in chromosomes 5 and 7 in myelodysplastic syndrome and acute myeloid leukemia. Ann Lab Med 45(2):133\u2013145","journal-title":"Ann Lab Med"},{"issue":"8","key":"6805_CR56","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.3390\/ijms25084259","volume":"25","author":"N Santoro","year":"2024","unstructured":"Santoro N et al (2024) Precision medicine approaches in acute myeloid leukemia with adverse genetics. Int J Mol Sci 25(8):4259","journal-title":"Int J Mol Sci"},{"issue":"15","key":"6805_CR57","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2010.28.3978","volume":"29","author":"J Schanz","year":"2011","unstructured":"Schanz J et al (2011) Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of Poor-Risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 29(15):1963\u20131970","journal-title":"J Clin Oncol"},{"issue":"7","key":"6805_CR58","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41375-019-0390-3","volume":"33","author":"K Mr\u00f3zek","year":"2019","unstructured":"Mr\u00f3zek K et al (2019) Complex karyotype in de Novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia 33(7):1620\u20131634","journal-title":"Leukemia"},{"issue":"26","key":"6805_CR59","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2017-12-822262","volume":"131","author":"T Inaba","year":"2018","unstructured":"Inaba T, Honda H, Matsui H (2018) The enigma of monosomy 7. Blood 131(26):2891\u20132898","journal-title":"Blood"},{"issue":"3","key":"6805_CR60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ccr.2013.08.011","volume":"24","author":"A Nagamachi","year":"2013","unstructured":"Nagamachi A et al (2013) Haploinsufficiency of <\u2009em\u2009>\u2009SAMD9L, an endosome fusion Facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. Cancer Cell 24(3):305\u2013317","journal-title":"Cancer Cell"},{"key":"6805_CR61","doi-asserted-by":"crossref","unstructured":"Zavras PD et al (2023) Understanding the continuum between High-Risk myelodysplastic syndrome and acute myeloid leukemia. Int J Mol Sci, 24(5)","DOI":"10.3390\/ijms24055018"},{"issue":"10","key":"6805_CR62","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-023-01996-9","volume":"37","author":"J Jung","year":"2023","unstructured":"Jung J et al (2023) Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest world health organization and the international consensus classifications. Leukemia 37(10):2125\u20132128","journal-title":"Leukemia"},{"issue":"7","key":"6805_CR63","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92(7):2322\u20132333","journal-title":"Blood"},{"issue":"12","key":"6805_CR64","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"6","key":"6805_CR65","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.25769","volume":"95","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G et al (2020) Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612\u2013622","journal-title":"Am J Hematol"},{"issue":"1","key":"6805_CR66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s44313-024-00044-4","volume":"59","author":"H Kim","year":"2024","unstructured":"Kim H et al (2024) Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia-related genes mutations and TP53 aberrations. Blood Res 59(1):41","journal-title":"Blood Res"},{"issue":"11","key":"6805_CR67","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.4081\/hr.2020.8957","volume":"12","author":"T Haferlach","year":"2020","unstructured":"Haferlach T (2020) Advancing leukemia diagnostics: role of next generation sequencing (NGS) in acute myeloid leukemia. Hematol Rep 12(11):8957","journal-title":"Hematol Rep"},{"key":"6805_CR68","doi-asserted-by":"crossref","unstructured":"Chin H-L et al (2023) Challenges associated with the identification of germline variants on myeloid malignancy genomic profiling\u2014a Singaporean experience. Front Oncol, Volume 13\u20132023","DOI":"10.3389\/fonc.2023.1182639"},{"issue":"12","key":"6805_CR69","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","volume":"9","author":"L Boscolo Bielo","year":"2023","unstructured":"Boscolo Bielo L et al (2023) Variant allele frequency: a decision-making tool in precision oncology? Trends Cancer 9(12):1058\u20131068","journal-title":"Trends Cancer"},{"issue":"Supplement 1","key":"6805_CR70","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2023-188968","volume":"142","author":"T Lee","year":"2023","unstructured":"Lee T et al (2023) Prognostic impact of variant allele frequency of Myelodysplasia-Related gene mutations among patients newly diagnosed as acute myeloid Leukemia, Myelodysplasia-Related according to the 5th world health organization classification. Blood 142(Supplement 1):2856\u20132856","journal-title":"Blood"},{"key":"6805_CR71","doi-asserted-by":"crossref","unstructured":"Park HS et al (2022) The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications. Ann Hematol, 101(12): pp. 2645\u20132654","DOI":"10.1007\/s00277-022-05002-7"},{"key":"6805_CR72","doi-asserted-by":"crossref","first-page":"p2856","DOI":"10.1182\/blood-2023-188968","volume":"142","author":"T Lee","year":"2023","unstructured":"Lee T et al (2023) Prognostic impact of variant allele frequency of Myelodysplasia-Related gene mutations among patients newly diagnosed as acute myeloid Leukemia, Myelodysplasia-Related according to the 5th world health organization classification. Blood 142:p2856\u2013p2856","journal-title":"Blood"},{"key":"6805_CR73","doi-asserted-by":"crossref","unstructured":"Sallman DA (2025) Can we harmonize classification of TP53 mutant MDS\/AML? Blood Advances, 9(13): pp. 3381\u20133382","DOI":"10.1182\/bloodadvances.2025016336"},{"issue":"6","key":"6805_CR74","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.27670","volume":"100","author":"S Fathima","year":"2025","unstructured":"Fathima S et al (2025) Multihit TP53 mutations in myeloproliferative neoplasms and acute myeloid leukemia: comparative analysis of survival and risk factors in 142 informative cases. Am J Hematol 100(6):1010\u20131018","journal-title":"Am J Hematol"},{"issue":"1","key":"6805_CR75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/hematology.2020006910","volume":"2020","author":"IL Kraft","year":"2020","unstructured":"Kraft IL, Godley LA (2020) Identifying potential germline variants from sequencing hematopoietic malignancies. Hematol Am Soc Hematol Educ Program 2020(1):219\u2013227","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"6805_CR76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s44313-024-00012-y","volume":"59","author":"SM Hwang","year":"2024","unstructured":"Hwang SM (2024) Genomic testing for germline predisposition to hematologic malignancies. Blood Res 59(1):12","journal-title":"Blood Res"},{"key":"6805_CR77","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fbioe.2020.00817","volume":"8","author":"B He","year":"2020","unstructured":"He B et al (2020) Assessing the impact of data preprocessing on analyzing next generation sequencing data. Front Bioeng Biotechnol 8:817","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"6805_CR78","doi-asserted-by":"crossref","first-page":"e0169774","DOI":"10.1371\/journal.pone.0169774","volume":"12","author":"V Potapov","year":"2017","unstructured":"Potapov V, Ong JL (2017) Examining sources of error in PCR by Single-Molecule sequencing. PLoS ONE 12(1):e0169774","journal-title":"PLoS ONE"},{"issue":"1","key":"6805_CR79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12859-016-0976-y","volume":"17","author":"M Schirmer","year":"2016","unstructured":"Schirmer M et al (2016) Illumina error profiles: resolving fine-scale variation in metagenomic sequencing data. BMC Bioinformatics 17(1):125","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"6805_CR80","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM et al (2016) Integrated digital error suppression for improved detection of Circulating tumor DNA. Nat Biotechnol 34(5):547\u2013555","journal-title":"Nat Biotechnol"},{"issue":"6","key":"6805_CR81","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C et al (2023) Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 37(6):1234\u20131244","journal-title":"Leukemia"},{"issue":"11","key":"6805_CR82","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s00277-023-05429-6","volume":"102","author":"Q Wang","year":"2023","unstructured":"Wang Q et al (2023) Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation. Ann Hematol 102(11):3061\u20133074","journal-title":"Ann Hematol"},{"issue":"8","key":"6805_CR83","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00277-022-04883-y","volume":"101","author":"O Wolach","year":"2022","unstructured":"Wolach O et al (2022) Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Ann Hematol 101(8):1719\u20131726","journal-title":"Ann Hematol"},{"issue":"5","key":"6805_CR84","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD et al (2018) Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in Small-Cell lung cancer. Cancer Cell 33(5):853\u2013861e4","journal-title":"Cancer Cell"},{"issue":"13","key":"6805_CR85","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S et al (2017) Rituximab after autologous Stem-Cell transplantation in Mantle-Cell lymphoma. N Engl J Med 377(13):1250\u20131260","journal-title":"N Engl J Med"},{"issue":"4","key":"6805_CR86","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"1","key":"6805_CR87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/acs.jproteome.0c00386","volume":"20","author":"T Sturm","year":"2021","unstructured":"Sturm T et al (2021) Mild acid elution and MHC immunoaffinity chromatography reveal similar albeit not identical profiles of the HLA class I immunopeptidome. J Proteome Res 20(1):289\u2013304","journal-title":"J Proteome Res"},{"issue":"5","key":"6805_CR88","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/leu.2014.314","volume":"29","author":"L Crucitti","year":"2015","unstructured":"Crucitti L et al (2015) Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia 29(5):1143\u20131152","journal-title":"Leukemia"},{"issue":"24","key":"6805_CR89","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ et al (2018) Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med 379(24):2330\u20132341","journal-title":"N Engl J Med"},{"issue":"1","key":"6805_CR90","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2119\/molmed.2015.00083","volume":"21","author":"A Lin","year":"2015","unstructured":"Lin A, Yan W-H (2015) Human leukocyte Antigen-G (HLA-G) expression in cancers: roles in immune Evasion, metastasis and target for therapy. Mol Med 21(1):782\u2013791","journal-title":"Mol Med"},{"issue":"1","key":"6805_CR91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5530\/ami.2017.4.10","volume":"4","author":"NA Hamed","year":"2017","unstructured":"Hamed NA et al (2017) Soluble HLA-G: A novel marker in acute myeloid leukemia patients. Acta Med Int 4(1):51\u201355","journal-title":"Acta Med Int"},{"issue":"1","key":"6805_CR92","doi-asserted-by":"crossref","first-page":"11444","DOI":"10.1038\/s41598-022-15020-0","volume":"12","author":"F Wang","year":"2022","unstructured":"Wang F et al (2022) PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway. Sci Rep 12(1):11444","journal-title":"Sci Rep"},{"issue":"1","key":"6805_CR93","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","volume":"7","author":"D Paola","year":"2019","unstructured":"Paola D et al (2019) Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer 7(1):175","journal-title":"J Immunother Cancer"},{"issue":"5","key":"6805_CR94","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.31557\/APJCP.2024.25.5.1777","volume":"25","author":"W El Dosoky","year":"2024","unstructured":"El Dosoky W et al (2024) Prognostic effect of CTLA4\/LAG3 expression by T-Cells subsets on acute myeloid leukemia patients. Asian Pac J Cancer Prev 25(5):1777\u20131785","journal-title":"Asian Pac J Cancer Prev"},{"key":"6805_CR95","doi-asserted-by":"crossref","unstructured":"Aval OS et al (2025) Galectin-9: A double-edged sword in acute myeloid leukemia. Annals of Hematology","DOI":"10.1007\/s00277-025-06387-x"},{"key":"6805_CR96","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14744\/ejmo.2023.35138","volume":"2023","author":"A Zahran","year":"2023","unstructured":"Zahran A et al (2023) Disturbed expression of memory T-Cell subsets could alter the outcomes in adult acute myeloid leukemia. Eurasian J Med Oncol 2023:362\u2013370","journal-title":"Eurasian J Med Oncol"},{"issue":"1","key":"6805_CR97","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12885-020-06961-8","volume":"20","author":"Y Wan","year":"2020","unstructured":"Wan Y et al (2020) Hyperfunction of CD4 CD25 regulatory T cells in de Novo acute myeloid leukemia. BMC Cancer 20(1):472","journal-title":"BMC Cancer"},{"key":"6805_CR98","doi-asserted-by":"crossref","unstructured":"Wang M et al (2018) Increased regulatory T cells in peripheral blood of acute myeloid leukemia patients rely on tumor necrosis factor (TNF)-\u03b1\u2013TNF Receptor-2 pathway. Front Immunol, 9\u20132018","DOI":"10.3389\/fimmu.2018.01274"},{"issue":"1","key":"6805_CR99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s44313-024-00048-0","volume":"59","author":"R Hakak","year":"2024","unstructured":"Hakak R, Poopak B, Majd A (2024) Increased IDO expression and regulatory T cells in acute myeloid leukemia: implications for immune escape and therapeutic targeting. Blood Res 59(1):42","journal-title":"Blood Res"},{"issue":"12","key":"6805_CR100","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00262-022-03217-1","volume":"71","author":"S Rahmani","year":"2022","unstructured":"Rahmani S, Yazdanpanah N, Rezaei N (2022) Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunol Immunother 71(12):2849\u20132867","journal-title":"Cancer Immunol Immunother"},{"key":"6805_CR101","doi-asserted-by":"crossref","unstructured":"Zhang F et al (2025) Beyond CAR-T: engineered NK cell therapies (CAR-NK, NKCEs) in Next-Generation cancer immunotherapy. Crit Rev Oncol\/Hematol, : p. 104912","DOI":"10.1016\/j.critrevonc.2025.104912"},{"issue":"6","key":"6805_CR102","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/cancers13061423","volume":"13","author":"S Sendker","year":"2021","unstructured":"Sendker S, Reinhardt D, Niktoreh N (2021) Redirecting the immune microenvironment in acute myeloid leukemia. Cancers 13(6):1423","journal-title":"Cancers"},{"issue":"1","key":"6805_CR103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-025-02228-5","volume":"10","author":"J Xie","year":"2025","unstructured":"Xie J et al (2025) Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia. Signal Transduct Target Therapy 10(1):143","journal-title":"Signal Transduct Target Therapy"},{"issue":"8","key":"6805_CR104","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485\u2013498","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"6805_CR105","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","volume":"129","author":"AR Pyzer","year":"2017","unstructured":"Pyzer AR et al (2017) MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 129(13):1791\u20131801","journal-title":"Blood"},{"key":"6805_CR106","doi-asserted-by":"crossref","unstructured":"Aghayan AH et al (2025) Extracellular Vesicle-Based biomarkers in diffuse large B-Cell lymphoma: A systematic review and Meta-Analysis. Crit Rev Oncol\/Hematol, : p. 104884","DOI":"10.1016\/j.critrevonc.2025.104884"},{"key":"6805_CR107","doi-asserted-by":"crossref","unstructured":"Kubaev A et al (2025) Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res, : p. 1\u201311","DOI":"10.1080\/08982104.2025.2495261"},{"issue":"14","key":"6805_CR108","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.3390\/cancers14143545","volume":"14","author":"X Roussel","year":"2022","unstructured":"Roussel X, Garnache F, Ottou, Renosi F (2022) Plasmacytoid dendritic Cells, a novel target in myeloid neoplasms. Cancers 14(14):3545","journal-title":"Cancers"},{"issue":"7","key":"6805_CR109","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","volume":"37","author":"S Huber","year":"2023","unstructured":"Huber S et al (2023) AML classification in the year 2023: how to avoid a Babylonian confusion of languages. Leukemia 37(7):1413\u20131420","journal-title":"Leukemia"},{"issue":"1","key":"6805_CR110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","volume":"25","author":"J Chen","year":"2019","unstructured":"Chen J et al (2019) Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med 25(1):103\u2013110","journal-title":"Nat Med"},{"issue":"1","key":"6805_CR111","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41232-021-00173-8","volume":"41","author":"M Ota","year":"2021","unstructured":"Ota M, Fujio K (2021) Multi-omics approach to precision medicine for immune-mediated diseases. Inflamm Regeneration 41(1):23","journal-title":"Inflamm Regeneration"},{"key":"6805_CR112","doi-asserted-by":"crossref","first-page":"1324212","DOI":"10.3389\/fphar.2023.1324212","volume":"14","author":"A Jiang","year":"2023","unstructured":"Jiang A et al (2023) Editorial: Multi-omics approaches for decoding heterogeneity in cancer immunotherapy. Front Pharmacol 14:1324212","journal-title":"Front Pharmacol"},{"issue":"1","key":"6805_CR113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41232-021-00173-8","volume":"41","author":"M Ota","year":"2021","unstructured":"Ota M, Fujio K (2021) Multi-omics approach to precision medicine for immune-mediated diseases. Inflamm Regen 41(1):23","journal-title":"Inflamm Regen"},{"key":"6805_CR114","unstructured":"Boumehira A et al (2022) Metabolomics approaches for early cancer diagnosis: a review. Asian Journal of Agriculture and Biology, 2022"},{"issue":"5","key":"6805_CR115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg.2018.4","volume":"19","author":"KJ Karczewski","year":"2018","unstructured":"Karczewski KJ, Snyder MP (2018) Integrative omics for health and disease. Nat Rev Genet 19(5):299\u2013310","journal-title":"Nat Rev Genet"},{"issue":"Supplement 1","key":"6805_CR116","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood-2023-185089","volume":"142","author":"WC Fiskus","year":"2023","unstructured":"Fiskus WC et al (2023) Pre-Clinical efficacy of CDK7 Inhibitor-Based combinations in cellular models of advanced myeloproliferative neoplasms (MPN) transformed to AML. Blood 142(Supplement 1):1783\u20131783","journal-title":"Blood"},{"issue":"24","key":"6805_CR117","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/bloodadvances.2019000677","volume":"3","author":"F Picou","year":"2019","unstructured":"Picou F et al (2019) Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv 3(24):4271\u20134279","journal-title":"Blood Adv"},{"key":"6805_CR118","doi-asserted-by":"crossref","unstructured":"Krassowski M et al (2020) State of the field in Multi-Omics research: from computational needs to data mining and sharing. Frontiers in Genetics, pp 11\u20132020","DOI":"10.3389\/fgene.2020.610798"},{"key":"6805_CR119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coisb.2017.08.009","volume":"6","author":"R Haas","year":"2017","unstructured":"Haas R et al (2017) Designing and interpreting \u2018multi-omic\u2019 experiments that May change our Understanding of biology. Curr Opin Syst Biology 6:37\u201345","journal-title":"Curr Opin Syst Biology"},{"issue":"6","key":"6805_CR120","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/leu.2011.383","volume":"26","author":"C Bachas","year":"2012","unstructured":"Bachas C et al (2012) The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 26(6):1313\u20131320","journal-title":"Leukemia"},{"key":"6805_CR121","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fonc.2019.00655","volume":"9","author":"MT Voso","year":"2019","unstructured":"Voso MT et al (2019) MRD in AML: the role of new techniques. Front Oncol 9:655","journal-title":"Front Oncol"},{"issue":"2","key":"6805_CR122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-019-0170-3","volume":"9","author":"M Yilmaz","year":"2019","unstructured":"Yilmaz M et al (2019) Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J 9(2):7","journal-title":"Blood Cancer J"},{"key":"6805_CR123","doi-asserted-by":"crossref","first-page":"603636","DOI":"10.3389\/fonc.2020.603636","volume":"10","author":"LL Ngai","year":"2020","unstructured":"Ngai LL et al (2020) MRD tailored therapy in AML: what we have learned so Far. Front Oncol 10:603636","journal-title":"Front Oncol"},{"key":"6805_CR124","unstructured":"Lucero J et al Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who May benefit from allogeneic hematopoietic stem cell transplantation"},{"key":"6805_CR125","doi-asserted-by":"crossref","unstructured":"Dix C et al (2020) Measurable residual disease in acute myeloid leukemia using flow cytometry: A review of where we are and where we are going. J Clin Med, 9(6)","DOI":"10.3390\/jcm9061714"},{"issue":"8","key":"6805_CR126","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3324\/haematol.2018.208454","volume":"104","author":"NJ Short","year":"2019","unstructured":"Short NJ, Ravandi F (2019) How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica 104(8):1532\u20131541","journal-title":"Haematologica"},{"key":"6805_CR127","unstructured":"Soleimani Samarkhazan H et al Nanosensors in Leukemia Management: Pioneering Real-Time Biomarker Detection for Precision Oncology. Nano Select. n\/a(n\/a): p. e70039"},{"issue":"1","key":"6805_CR128","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","volume":"6","author":"JM Tettero","year":"2022","unstructured":"Tettero JM et al (2022) Technical aspects of flow Cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD working party. Hemasphere 6(1):e676","journal-title":"Hemasphere"},{"issue":"2","key":"6805_CR129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jclinpath-2016-203863","volume":"70","author":"OK Weinberg","year":"2017","unstructured":"Weinberg OK et al (2017) Assessment of myeloid and monocytic dysplasia by flow cytometry in de Novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol 70(2):109\u2013115","journal-title":"J Clin Pathol"},{"issue":"11","key":"6805_CR130","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","volume":"2","author":"F Ravandi","year":"2018","unstructured":"Ravandi F, Walter RB, Freeman SD (2018) Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv 2(11):1356\u20131366","journal-title":"Blood Adv"},{"issue":"5","key":"6805_CR131","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","volume":"4","author":"A Ediriwickrema","year":"2020","unstructured":"Ediriwickrema A et al (2020) Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Adv 4(5):943\u2013952","journal-title":"Blood Adv"},{"issue":"20","key":"6805_CR132","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","volume":"135","author":"RP Hasserjian","year":"2020","unstructured":"Hasserjian RP et al (2020) Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood 135(20):1729\u20131738","journal-title":"Blood"},{"key":"6805_CR133","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1182\/blood-2024-205645","volume":"144","author":"A Condorelli","year":"2024","unstructured":"Condorelli A et al (2024) Optimizing acute myeloid leukemia monitoring: A novel Multi-Target NGS application for measurable residual disease assessment. Blood 144:6169","journal-title":"Blood"},{"key":"6805_CR134","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Herrero E et al (2022) Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that May impact on ctdna analysis. Front Oncol, Volume 12\u20132022","DOI":"10.3389\/fonc.2022.943253"},{"key":"6805_CR135","doi-asserted-by":"crossref","first-page":"104986","DOI":"10.1016\/j.cellimm.2025.104986","volume":"414","author":"I Ahmad","year":"2025","unstructured":"Ahmad I et al (2025) Mesenchymal stem cell-derived exosomes (MSC-exosomes) in hematology: from mechanisms to clinical breakthroughs. Cell Immunol 414:104986","journal-title":"Cell Immunol"},{"issue":"6","key":"6805_CR136","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ et al (2025) Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol 42(6):199","journal-title":"Med Oncol"},{"issue":"3","key":"6805_CR137","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon DW et al (2020) Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 1(3):276\u2013290","journal-title":"Nat Cancer"},{"issue":"23","key":"6805_CR138","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","volume":"26","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM et al (2020) A phase Ib study of Onvansertib, a novel oral PLK1 Inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia. Clin Cancer Res 26(23):6132\u20136140","journal-title":"Clin Cancer Res"},{"key":"6805_CR139","doi-asserted-by":"crossref","unstructured":"Ruan M et al (2021) Targeted Next-Generation sequencing of Circulating tumor DNA, bone Marrow, and peripheral blood mononuclear cells in pediatric AML. Front Oncol, 11\u20132021","DOI":"10.3389\/fonc.2021.666470"},{"issue":"11","key":"6805_CR140","first-page":"107","volume":"2","author":"M Ilie","year":"2014","unstructured":"Ilie M et al (2014) Current challenges for detection of Circulating tumor cells and cell-free Circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Annals Translational Med 2(11):107","journal-title":"Annals Translational Med"},{"issue":"1","key":"6805_CR141","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","volume":"70","author":"P van der Leest","year":"2024","unstructured":"van der Leest P, Schuuring E (2024) Critical factors in the analytical work flow of Circulating tumor DNA-Based molecular profiling. Clin Chem 70(1):220\u2013233","journal-title":"Clin Chem"},{"issue":"31","key":"6805_CR142","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LSG \u00d8stg\u00e5rd","year":"2015","unstructured":"\u00d8stg\u00e5rd LSG et al (2015) Epidemiology and clinical significance of secondary and Therapy-Related acute myeloid leukemia: A National Population-Based cohort study. J Clin Oncol 33(31):3641\u20133649","journal-title":"J Clin Oncol"},{"issue":"7457","key":"6805_CR143","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214\u2013218","journal-title":"Nature"},{"issue":"10","key":"6805_CR144","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N et al (2020) New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10(10):107","journal-title":"Blood Cancer J"},{"issue":"26","key":"6805_CR145","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE et al (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36(26):2684\u20132692","journal-title":"J Clin Oncol"},{"key":"6805_CR146","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","volume":"14","author":"LD Mayer","year":"2019","unstructured":"Mayer LD, Tardi P, Louie AC (2019) CPX-351: a nanoscale liposomal co-formulation of Daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomed 14:3819\u20133830","journal-title":"Int J Nanomed"},{"issue":"6","key":"6805_CR147","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/bloodadvances.2020003510","volume":"5","author":"TL Lin","year":"2021","unstructured":"Lin TL et al (2021) Older adults with newly diagnosed high-risk\/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv 5(6):1719\u20131728","journal-title":"Blood Adv"},{"issue":"1","key":"6805_CR148","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","volume":"5","author":"E Chiche","year":"2021","unstructured":"Chiche E et al (2021) Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv 5(1):176\u2013184","journal-title":"Blood Adv"},{"issue":"10","key":"6805_CR149","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","volume":"11","author":"C Rautenberg","year":"2021","unstructured":"Rautenberg C et al (2021) Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J 11(10):164","journal-title":"Blood Cancer J"},{"issue":"4","key":"6805_CR150","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/bloodadvances.2024014279","volume":"9","author":"T Cluzeau","year":"2025","unstructured":"Cluzeau T et al (2025) Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS. Blood Adv 9(4):752\u2013758","journal-title":"Blood Adv"},{"issue":"1","key":"6805_CR151","first-page":"115","volume":"109","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2024","unstructured":"Mart\u00ednez-Cuadr\u00f3n D et al (2024) Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry. Haematologica 109(1):115\u2013128","journal-title":"Haematologica"},{"issue":"31","key":"6805_CR152","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS et al (2015) Epidemiology and clinical significance of secondary and Therapy-Related acute myeloid leukemia: A National Population-Based cohort study. J Clin Oncol 33(31):3641\u20133649","journal-title":"J Clin Oncol"},{"issue":"10","key":"6805_CR153","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.leukres.2012.07.006","volume":"36","author":"EJ Feldman","year":"2012","unstructured":"Feldman EJ et al (2012) Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res 36(10):1283\u20131289","journal-title":"Leuk Res"},{"key":"6805_CR154","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CEOR.S342303","volume":"14","author":"K Price","year":"2022","unstructured":"Price K et al (2022) Comparison of hospital length of stay and supportive care utilization between patients treated with CPX-351 and 7\u2009+\u20093 for Therapy-Related acute myeloid leukemia or acute myeloid leukemia with Myelodysplasia-Related changes. ClinicoEconomics Outcomes Res 14:21\u201334","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"6805_CR155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CEOR.S342303","volume":"14","author":"K Price","year":"2022","unstructured":"Price K et al (2022) Comparison of hospital length of stay and supportive care utilization between patients treated with CPX-351 and 7\u2009+\u20093 for Therapy-Related acute myeloid leukemia or acute myeloid leukemia with Myelodysplasia-Related changes. Clinicoecon Outcomes Res 14:21\u201334","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"6805_CR156","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13148-016-0233-2","volume":"8","author":"S Yun","year":"2016","unstructured":"Yun S et al (2016) Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin Epigenetics 8(1):68","journal-title":"Clin Epigenetics"},{"issue":"7","key":"6805_CR157","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J et al (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35(7):1873\u20131889","journal-title":"Leukemia"},{"issue":"10","key":"6805_CR158","doi-asserted-by":"crossref","first-page":"e0238795","DOI":"10.1371\/journal.pone.0238795","volume":"15","author":"P Bories","year":"2020","unstructured":"Bories P et al (2020) Impact of TP53 mutations in acute myeloid leukemia patients treated with Azacitidine. PLoS ONE 15(10):e0238795","journal-title":"PLoS ONE"},{"issue":"4","key":"6805_CR159","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","volume":"25","author":"AP Kater","year":"2024","unstructured":"Kater AP et al (2024) Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. Lancet Oncol 25(4):463\u2013473","journal-title":"Lancet Oncol"},{"issue":"2","key":"6805_CR160","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM et al (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21(2):178\u2013184","journal-title":"Nat Med"},{"key":"6805_CR161","first-page":"212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo LM, Desai V, Dalia S (2019) Venetoclax: evidence to date and clinical potential. Drugs Context 8:212574","journal-title":"Drugs Context"},{"issue":"11","key":"6805_CR162","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14656566.2023.2218545","volume":"24","author":"AR Lovell","year":"2023","unstructured":"Lovell AR, Sawyers J, Bose P (2023) An update on the efficacy of venetoclax for chronic lymphocytic leukemia. Expert Opin Pharmacother 24(11):1307\u20131316","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"6805_CR163","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3923\/ijp.2023.632.641","volume":"19","author":"Q Su","year":"2023","unstructured":"Su Q et al (2023) Dihydroartemisinin increases the sensitivity of acute myeloid leukemia cells to cytarabine via the Nrf2\/HO-1 Anti-Oxidant signaling pathway. IJP 19(5):632\u2013641","journal-title":"IJP"},{"key":"6805_CR164","doi-asserted-by":"crossref","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J et al (2022) Mechanisms of venetoclax resistance and solutions. Front Oncol 12:1005659","journal-title":"Front Oncol"},{"issue":"15","key":"6805_CR165","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH et al (2019) Venetoclax combined with Low-Dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37(15):1277\u20131284","journal-title":"J Clin Oncol"},{"issue":"7","key":"6805_CR166","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"6805_CR167","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1182\/blood-2024-199990","volume":"144","author":"J Zhang","year":"2024","unstructured":"Zhang J et al (2024) Efficacy and safety of venetoclax in combination with hypomethylating agents for the treatment of High-Risk myelodysplastic Syndromes\u2013Real-World analyses. Blood 144(Supplement 1):6732\u20136732","journal-title":"Blood"},{"issue":"9","key":"6805_CR168","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","volume":"23","author":"A Letai","year":"2017","unstructured":"Letai A (2017) Functional precision cancer medicine-moving beyond pure genomics. Nat Med 23(9):1028\u20131035","journal-title":"Nat Med"},{"issue":"1","key":"6805_CR169","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL (2022) Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40(1):26\u201335","journal-title":"Cancer Cell"},{"key":"6805_CR170","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Medina C et al (2024) Biomarkers of response to venetoclax therapy in acute myeloid leukemia. Int J Mol Sci, 25(3)","DOI":"10.3390\/ijms25031421"},{"issue":"2","key":"6805_CR171","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"G Del Moore","year":"2013","unstructured":"Del Moore G, V. and, Letai A (2013) BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332(2):202\u2013205","journal-title":"Cancer Lett"},{"issue":"6","key":"6805_CR172","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1097\/HS9.0000000000000912","volume":"7","author":"AH Wei","year":"2023","unstructured":"Wei AH, Roberts AW (2023) BCL2 inhibition: A new paradigm for the treatment of AML and beyond. Hemasphere 7(6):e912","journal-title":"Hemasphere"},{"issue":"7","key":"6805_CR173","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"ARD Delbridge","year":"2015","unstructured":"Delbridge ARD, Strasser A (2015) The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 22(7):1071\u20131080","journal-title":"Cell Death Differ"},{"issue":"1","key":"6805_CR174","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13046-021-02157-5","volume":"40","author":"PA Townsend","year":"2021","unstructured":"Townsend PA et al (2021) BH3-mimetics: recent developments in cancer therapy. J Experimental Clin Cancer Res 40(1):355","journal-title":"J Experimental Clin Cancer Res"},{"key":"6805_CR175","doi-asserted-by":"crossref","unstructured":"Bouligny IM et al (2023) Venetoclax with decitabine or Azacitidine in relapsed or refractory acute myeloid leukemia. Res Sq","DOI":"10.21203\/rs.3.rs-3015916\/v1"},{"issue":"4","key":"6805_CR176","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","volume":"30","author":"AM De La Acanda","year":"2024","unstructured":"De La Acanda AM et al (2024) Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat Med 30(4):990\u20131000","journal-title":"Nat Med"},{"issue":"2","key":"6805_CR177","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C et al (2022) Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov 12(2):372\u2013387","journal-title":"Cancer Discov"},{"issue":"1","key":"6805_CR178","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A et al (2025) Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Experimental Med 25(1):186","journal-title":"Clin Experimental Med"},{"issue":"1","key":"6805_CR179","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK et al (2025) Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Experimental Med 25(1):166","journal-title":"Clin Experimental Med"},{"issue":"14","key":"6805_CR180","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.3390\/cancers14143398","volume":"14","author":"TE Knight","year":"2022","unstructured":"Knight TE et al (2022) FLipping the story: FLT3-Mutated acute myeloid leukemia and the evolving role of FLT3 inhibitors. Cancers 14(14):3398","journal-title":"Cancers"},{"issue":"20","key":"6805_CR181","doi-asserted-by":"crossref","first-page":"12708","DOI":"10.3390\/ijms232012708","volume":"23","author":"M-K Song","year":"2022","unstructured":"Song M-K, Park B-B, Uhm J-E (2022) Clinical efficacies of FLT3 inhibitors in patients with acute myeloid leukemia. Int J Mol Sci 23(20):12708","journal-title":"Int J Mol Sci"},{"issue":"28","key":"6805_CR182","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T et al (2010) Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28(28):4339\u20134345","journal-title":"J Clin Oncol"},{"issue":"4","key":"6805_CR183","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I (2020) Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest 130(4):1552\u20131564","journal-title":"J Clin Invest"},{"issue":"1","key":"6805_CR184","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S et al (2025) Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res 13(1):73","journal-title":"Biomark Res"},{"issue":"1","key":"6805_CR185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H et al (2025) Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Experimental Med 25(1):215","journal-title":"Clin Experimental Med"},{"issue":"12","key":"6805_CR186","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69(12):4941\u20134944","journal-title":"Cancer Res"},{"key":"6805_CR187","doi-asserted-by":"crossref","unstructured":"Ravandi F et al (2024) Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study, vol 65. Leukemia & Lymphoma, pp 1281\u20131291. 9","DOI":"10.1080\/10428194.2024.2346755"},{"issue":"9","key":"6805_CR188","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","volume":"65","author":"F Ravandi","year":"2024","unstructured":"Ravandi F et al (2024) Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study. Leuk Lymphoma 65(9):1281\u20131291","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"6805_CR189","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood-2023-182891","volume":"142","author":"G Li","year":"2023","unstructured":"Li G et al (2023) Novel CD123xCD3 bispecific Igm Antibody, Igm-2537, potently induces T-Cell mediated cytotoxicity of acute myeloid leukemia cells in vivo and in vitro with minimal cytokine release. Blood 142(Supplement 1):4177\u20134177","journal-title":"Blood"},{"key":"6805_CR190","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood-2023-182891","volume":"142","author":"G Li","year":"2023","unstructured":"Li G et al (2023) Novel CD123xCD3 bispecific Igm Antibody, Igm-2537, potently induces T-Cell mediated cytotoxicity of acute myeloid leukemia cells in vivo and in vitro with minimal cytokine release. Blood 142:4177","journal-title":"Blood"},{"issue":"3","key":"6805_CR191","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","volume":"16","author":"J Mueller","year":"2024","unstructured":"Mueller J et al (2024) Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells. EMBO Mol Med 16(3):445\u2013474","journal-title":"EMBO Mol Med"},{"issue":"Pt 1","key":"6805_CR192","doi-asserted-by":"crossref","first-page":"129332","DOI":"10.1016\/j.ijbiomac.2024.129332","volume":"260","author":"H Yang","year":"2024","unstructured":"Yang H et al (2024) TMEM64 aggravates the malignant phenotype of glioma by activating the Wnt\/\u03b2-catenin signaling pathway. Int J Biol Macromol 260(Pt 1):129332","journal-title":"Int J Biol Macromol"},{"issue":"20","key":"6805_CR193","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","volume":"4","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J et al (2020) TP53 abnormalities correlate with immune infiltration and associate with response to Flotetuzumab immunotherapy in AML. Blood Adv 4(20):5011\u20135024","journal-title":"Blood Adv"},{"issue":"1","key":"6805_CR194","doi-asserted-by":"crossref","first-page":"2400363","DOI":"10.1002\/adtp.202400363","volume":"8","author":"B Wu","year":"2025","unstructured":"Wu B et al (2025) Dimethyl fumarate augments anticancer activity of \u00c5ngstrom silver particles in myeloma cells through NRF2 activation. Adv Ther 8(1):2400363","journal-title":"Adv Ther"},{"issue":"3","key":"6805_CR195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153\u2013167","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"6805_CR196","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-017-0403-5","volume":"10","author":"J Wang","year":"2017","unstructured":"Wang J et al (2017) PD-1, PD-L1 (B7-H1) and Tumor-Site immune modulation therapy: the historical perspective. J Hematol Oncol 10(1):34","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6805_CR197","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L (2018) A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2):313\u2013326","journal-title":"Cell"},{"issue":"18","key":"6805_CR198","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X et al (2023) A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186(18):3903\u20133920e21","journal-title":"Cell"},{"issue":"3","key":"6805_CR199","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N et al (2019) Efficacy, Safety, and biomarkers of response to Azacitidine and nivolumab in Relapsed\/Refractory acute myeloid leukemia: A Nonrandomized, Open-Label, phase II study. Cancer Discov 9(3):370\u2013383","journal-title":"Cancer Discov"},{"issue":"1","key":"6805_CR200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H et al (2025) The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Exp Med 25(1):240","journal-title":"Clin Exp Med"},{"key":"6805_CR201","doi-asserted-by":"crossref","first-page":"659595","DOI":"10.3389\/fimmu.2021.659595","volume":"12","author":"J Loke","year":"2021","unstructured":"Loke J, Buka R, Craddock C (2021) Allogeneic stem cell transplantation for acute myeloid leukemia: Who, When, and how? Front Immunol 12:659595","journal-title":"Front Immunol"},{"issue":"3","key":"6805_CR202","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.bbmt.2018.12.394","volume":"25","author":"Y Lee","year":"2019","unstructured":"Lee Y et al (2019) Myeloid leukemia with Myelodysplasia-Related changes was not a prognostic factor under allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 25(3):S117","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"6805_CR203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A et al (2025) Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Experimental Med 25(1):73","journal-title":"Clin Experimental Med"},{"key":"6805_CR204","doi-asserted-by":"crossref","unstructured":"Soleimani Samarkhazan H et al (2025) The microbiome in graft-versus-host disease: a tale of two ecosystems. Journal of Translational Medicine, 23(1): p. 832","DOI":"10.1186\/s12967-025-06797-5"},{"key":"6805_CR205","doi-asserted-by":"crossref","unstructured":"Boukovala M, Westphalen CB, Probst V (2024) Liquid biopsy into the clinics: current evidence and future perspectives. J Liquid Biopsy, 4","DOI":"10.1016\/j.jlb.2024.100146"},{"issue":"1","key":"6805_CR206","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H et al (2025) C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep 52(1):464","journal-title":"Mol Biol Rep"},{"issue":"1","key":"6805_CR207","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H et al (2025) Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res 13(1):28","journal-title":"Biomark Res"},{"issue":"1","key":"6805_CR208","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L et al (2024) Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Therapy 9(1):336","journal-title":"Signal Transduct Target Therapy"},{"key":"6805_CR209","doi-asserted-by":"crossref","unstructured":"Abbasi EY et al (2024) A machine learning and deep learning-based integrated multi-omics technique for leukemia prediction. Heliyon, 10(3)","DOI":"10.1016\/j.heliyon.2024.e25369"},{"key":"6805_CR210","doi-asserted-by":"crossref","unstructured":"Guo X et al (2024) Preliminary screening of biomarkers and drug candidates in a mouse model of \u03b2-thalassemia based on quasi-targeted metabolomics. Front Physiol, Volume 15\u20132024","DOI":"10.3389\/fphys.2024.1452558"},{"issue":"1","key":"6805_CR211","doi-asserted-by":"crossref","first-page":"31","DOI":"10.33633\/jcta.v1i1.9185","volume":"1","author":"MA Araaf","year":"2023","unstructured":"Araaf MA, Nugroho K, Setiadi DRIM (2023) Comprehensive analysis and classification of skin diseases based on image texture features using K-nearest neighbors algorithm. J Comput Theor Appl 1(1):31\u201340","journal-title":"J Comput Theor Appl"},{"key":"6805_CR212","doi-asserted-by":"crossref","unstructured":"Mohr AE et al (2024) Navigating challenges and opportunities in Multi-Omics integration for personalized healthcare. Biomedicines, 12(7)","DOI":"10.3390\/biomedicines12071496"},{"key":"6805_CR213","first-page":"1","volume":"PP","author":"G Xu","year":"2025","unstructured":"Xu G et al (2025) Anonymity-Enhanced sequential Multi-Signer ring signature for secure medical data sharing in IoMT. IEEE Trans Inf Forensics Secur PP:1\u20131","journal-title":"IEEE Trans Inf Forensics Secur"},{"issue":"3","key":"6805_CR214","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1039\/D4PM00323C","volume":"2","author":"JPS Saini","year":"2025","unstructured":"Saini JPS, Thakur A, Yadav D (2025) AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations. RSC Pharm 2(3):437\u2013454","journal-title":"RSC Pharm"},{"issue":"1","key":"6805_CR215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12943-025-02321-x","volume":"24","author":"Y Mao","year":"2025","unstructured":"Mao Y et al (2025) Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges. Mol Cancer 24(1):123","journal-title":"Mol Cancer"},{"key":"6805_CR216","doi-asserted-by":"crossref","unstructured":"Yeh SJ et al (2024) TransCell: in Silico characterization of genomic landscape and cellular responses by deep transfer learning. Genomics Proteom Bioinf, 22(2)","DOI":"10.1093\/gpbjnl\/qzad008"},{"issue":"1","key":"6805_CR217","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1038\/s41467-020-19313-8","volume":"11","author":"J Kong","year":"2020","unstructured":"Kong J et al (2020) Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat Commun 11(1):5485","journal-title":"Nat Commun"},{"issue":"12","key":"6805_CR218","doi-asserted-by":"crossref","first-page":"e70048","DOI":"10.1002\/hem3.70048","volume":"8","author":"T Ghete","year":"2024","unstructured":"Ghete T et al (2024) Models for the marrow: A comprehensive review of AI-based cell classification methods and malignancy detection in bone marrow aspirate smears. HemaSphere 8(12):e70048","journal-title":"HemaSphere"},{"issue":"1","key":"6805_CR219","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/bloodadvances.2023011076","volume":"8","author":"J Kockwelp","year":"2023","unstructured":"Kockwelp J et al (2023) Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears. Blood Adv 8(1):70\u201379","journal-title":"Blood Adv"},{"issue":"1","key":"6805_CR220","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41467-025-58921-0","volume":"16","author":"G Zhang","year":"2025","unstructured":"Zhang G et al (2025) TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data. Nat Commun 16(1):3611","journal-title":"Nat Commun"},{"issue":"18","key":"6805_CR221","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.3390\/jcm12185940","volume":"12","author":"H Lee","year":"2023","unstructured":"Lee H et al (2023) Machine learning predicts 30-Day outcome among acute myeloid leukemia patients: A Single-Center, Retrospective, cohort study. J Clin Med 12(18):5940","journal-title":"J Clin Med"},{"key":"6805_CR222","doi-asserted-by":"crossref","first-page":"108735","DOI":"10.1016\/j.compbiomed.2024.108735","volume":"178","author":"\u0391 Kosvyra","year":"2024","unstructured":"Kosvyra \u0391 et al (2024) Machine learning and integrative multi-omics network analysis for survival prediction in acute myeloid leukemia. Comput Biol Med 178:108735","journal-title":"Comput Biol Med"},{"issue":"9","key":"6805_CR223","first-page":"2435","volume":"108","author":"V Clichet","year":"2023","unstructured":"Clichet V et al (2023) Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry. Haematologica 108(9):2435\u20132443","journal-title":"Haematologica"},{"issue":"4","key":"6805_CR224","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cyto.b.22166","volume":"106","author":"DP Ng","year":"2024","unstructured":"Ng DP et al (2024) Recommendations for using artificial intelligence in clinical flow cytometry. Cytometry B Clin Cytom 106(4):228\u2013238","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"6805_CR225","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/clinchem\/hvae126","volume":"70","author":"NC Spies","year":"2024","unstructured":"Spies NC et al (2024) Validating, Implementing, and monitoring machine learning solutions in the clinical laboratory safely and effectively. Clin Chem 70(11):1334\u20131343","journal-title":"Clin Chem"},{"issue":"16","key":"6805_CR226","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/bloodadvances.2020004055","volume":"5","author":"HS Oster","year":"2021","unstructured":"Oster HS et al (2021) A predictive algorithm using clinical and laboratory parameters May assist in ruling out and in diagnosing MDS. Blood Adv 5(16):3066\u20133075","journal-title":"Blood Adv"},{"key":"6805_CR227","doi-asserted-by":"crossref","first-page":"1635475","DOI":"10.3389\/fpubh.2025.1635475","volume":"13","author":"F Hu","year":"2025","unstructured":"Hu F et al (2025) Innovation networks in the advanced medical equipment industry: supporting regional digital health systems from a local-national perspective. Front Public Health 13:1635475","journal-title":"Front Public Health"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06805-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06805-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06805-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:00:45Z","timestamp":1776405645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06805-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":227,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6805"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06805-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}